- Home
- RNTX vs SGRP Comparison
RNTX vs SGRP Comparison
Compare RNTX & SGRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- SGRP
- Stock Information
- Founded
- RNTX 2001
- SGRP 1967
- Country
- RNTX United States
- SGRP United States
- Employees
- RNTX N/A
- SGRP N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- SGRP Business Services
- Sector
- RNTX Health Care
- SGRP Consumer Discretionary
- Exchange
- RNTX Nasdaq
- SGRP Nasdaq
- Market Cap
- RNTX 28.0M
- SGRP 28.2M
- IPO Year
- RNTX N/A
- SGRP 1996
- Fundamental
- Price
- RNTX $1.15
- SGRP $1.12
- Analyst Decision
- RNTX Hold
- SGRP
- Analyst Count
- RNTX 1
- SGRP 0
- Target Price
- RNTX N/A
- SGRP N/A
- AVG Volume (30 Days)
- RNTX 133.3K
- SGRP 298.4K
- Earning Date
- RNTX 11-13-2025
- SGRP 11-13-2025
- Dividend Yield
- RNTX N/A
- SGRP N/A
- EPS Growth
- RNTX N/A
- SGRP N/A
- EPS
- RNTX N/A
- SGRP N/A
- Revenue
- RNTX N/A
- SGRP $143,501,000.00
- Revenue This Year
- RNTX N/A
- SGRP $7.22
- Revenue Next Year
- RNTX N/A
- SGRP N/A
- P/E Ratio
- RNTX N/A
- SGRP N/A
- Revenue Growth
- RNTX N/A
- SGRP N/A
- 52 Week Low
- RNTX $1.04
- SGRP $0.91
- 52 Week High
- RNTX $4.40
- SGRP $2.48
- Technical
- Relative Strength Index (RSI)
- RNTX 45.62
- SGRP 45.30
- Support Level
- RNTX $1.07
- SGRP $1.08
- Resistance Level
- RNTX $1.25
- SGRP $1.18
- Average True Range (ATR)
- RNTX 0.14
- SGRP 0.05
- MACD
- RNTX -0.01
- SGRP -0.01
- Stochastic Oscillator
- RNTX 21.33
- SGRP 15.38
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About SGRP SPAR Group Inc.
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.